Correlation between changes after 24 weeks treatment in body weight and creatinine eGFR ( A ), cystatin-C eGFR ( B ) and iohexol mGFR ( C )
2013 Mar;154(5):681-5
Some online marketplaces now feature dedicated filters for GLP-1-friendly" products, automatically prioritizing items with lean protein and fibre while excluding refined carbohydrates and excess saturated fat
We also proposed that if more recent data subsequently become available after the publication of the CY 2026 OPPS/ASC proposed rule (for example, a more recent estimate of the market basket percentage increase and/or the productivity adjustment), we would use such data, if appropriate, to determine the CY 2026 hospital inpatient market basket update and the productivity adjustment for the final rule with comment period, which are components in calculating the OPD fee schedule increase factor under sections 1833(t)(3)(C)(iv) and 1833(t)(3)(F) of the Act
Along with the new oral version of the GLP-1 agonist that has made a strong commercial start since its launch in the US earlier this year, the high-dose injectable version is one of the assets Novo Nordisk is hoping will help staunch the loss in market share in obesity caused by the rapid growth of Wegovy's main rival, Eli Lilly's Zepbound/Mounjaro (tirzepatide), which outperformed the original 2.4 mg Wegovy formulation in head-to-head trials
Some research suggests that certain macrolides can occasionally lead to lower blood sugar when used alongside diabetes medications
